Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | SVP, Chief Regulatory Affairs | May 22, 2018 | May 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date May 22, 2018 · Filed May 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,936 |
Ending reported balance
After 2018-05-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-05-22 · Exercise / conversion · Acquired 4,432 · Balance 33,241 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2018-05-22 · Tax withholding · Disposed 1,305 · Balance 31,936 F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-22 · Exercise / conversion · Disposed 4,432 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017.
F3: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
REATA PHARMACEUTICALS INC
Report date September 26, 2023 · Filed September 26, 2023
Section 16 reporting ended · disclosed 2023-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 1
1 source rowRow 1 · 2023-09-26 · Disposition to issuer · Disposed 7,359 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.20 · Expires 2031-04-15 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-26 · Disposition to issuer · Disposed 3,334 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $146.01 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-26 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $146.01 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-26 · Disposition to issuer · Disposed 780 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.76 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-26 · Disposition to issuer · Disposed 443 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.76 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-26 · Disposition to issuer · Disposed 1,405 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.61 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-26 · Disposition to issuer · Disposed 576 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.61 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-26 · Disposition to issuer · Disposed 2,137 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)
F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2017 Filed Oct 5, 2017 23:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 11,500 | $14.76 Strike: $14.76 | $169,740.00 |
DisclosureSEC source: 0001209191-17-056202 · doc4.xml · derivative · entry 3 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,144 Underlying: Common Stock · 11,500 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 11,500 | $50.00 | $575,000.00 |
DisclosureSEC source: 0001209191-17-056202 · doc4.xml · nonDerivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,045 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 11,500 | $14.76 | $169,740.00 |
DisclosureSEC source: 0001209191-17-056202 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:44 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 8,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047903 · doc4.xml · derivative · entry 3 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. F3 · derivative.expiration_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:44 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,882 | $37.88 | $109,170.16 |
DisclosureSEC source: 0001209191-17-047903 · doc4.xml · nonDerivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,045 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:44 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 8,865 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047903 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,500 | $14.76 Strike: $14.76 | $22,140.00 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · derivative · entry 9 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,644 Underlying: Common Stock · 1,500 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 4,388 | $13.90 Strike: $13.90 | $60,993.20 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · derivative · entry 8 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,098 Underlying: Common Stock · 4,388 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 1,500 | $44.00 | $66,000.00 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · nonDerivative · entry 6 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,062 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,500 | $14.76 | $22,140.00 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · nonDerivative · entry 5 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 4,388 | $44.00 | $193,072.00 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · nonDerivative · entry 4 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,062 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 4,388 | $13.90 | $60,993.20 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · nonDerivative · entry 3 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 6,250 | $13.71 Strike: $13.71 | $85,687.50 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · derivative · entry 7 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,708 Underlying: Common Stock · 6,250 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 6,250 | $42.00 | $262,500.00 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · nonDerivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,062 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 6,250 | $13.71 | $85,687.50 |
DisclosureSEC source: 0001209191-17-046037 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| March 19, 2017 Filed Mar 21, 2017 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 177 | $30.30 | $5,363.10 |
DisclosureSEC source: 0001209191-17-022104 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,062 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock granted on 9/19/2016. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:50 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantIncentive Stock Option (right to buy) · Derivative | 4,189 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020691 · doc4.xml · derivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,189 Underlying: Common Stock · 4,189 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:50 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,811 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020691 · doc4.xml · derivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,811 Underlying: Common Stock · 20,811 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 13:20 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $26.24 | $0.00 |
DisclosureSEC source: 0001209191-16-149228 · doc4.xml · derivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,097 Underlying: Common Stock · 1,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option became exercisable on the first anniversary of the date of hire (01/02/2013) and 1/48th of the total granted option becomes exercisable on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 13:20 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,000 | $26.24 | $26,240.00 |
DisclosureSEC source: 0001209191-16-149228 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. Read SEC document |
| September 22, 2016 Filed Oct 1, 2016 01:58 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 7,311 | $13.90 Strike: $13.90 | $101,622.90 |
DisclosureSEC source: 0001209191-16-143452 · doc4.xml · derivative · entry 3 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,486 Underlying: Common Stock · 7,311 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Oct 1, 2016 01:58 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 7,311 | $60.00 | $438,660.00 |
DisclosureSEC source: 0001209191-16-143452 · doc4.xml · nonDerivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,239 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Oct 1, 2016 01:58 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 7,311 | $13.90 | $101,622.90 |
DisclosureSEC source: 0001209191-16-143452 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.